The relationship of eosinophilia to intravenous immunoglobulin treatment failure in Kawasaki disease

2007 ◽  
Vol 18 (4) ◽  
pp. 354-359 ◽  
Author(s):  
Ho-Chang Kuo ◽  
Kuender D. Yang ◽  
Chi-Di Liang ◽  
Chin-Nam Bong ◽  
Hong-Ren Yu ◽  
...  
Author(s):  
Ryusuke Ae ◽  
Joseph Y. Abrams ◽  
Ryan A. Maddox ◽  
Lawrence B. Schonberger ◽  
Yosikazu Nakamura ◽  
...  

BACKGROUND Randomized controlled trials previously provided different conclusions about the superiority of adding corticosteroids to initial intravenous immunoglobulin treatment for the prevention of coronary artery abnormalities in patients with Kawasaki disease (KD). To further assess this issue, we analyzed large‐scale data from nationwide KD surveys in Japan, where combination treatment (corticosteroids added to initial standard intravenous immunoglobulin treatment) has become commonly used for patients at high risk for KD. METHODS AND RESULTS Standard intravenous immunoglobulin treatment and combination treatment were compared using data from time periods with and without combination treatment. Outcome measures were coronary artery abnormalities and initial intravenous immunoglobulin treatment failure. Hospitals where ≥20% of patients received combination treatment were identified, and treatment and control groups were selected via matching by age, sex, illness day at initial treatment, and KD recurrence. Matched group selection and subsequent analyses were conducted 1000 times to minimize sampling bias and potential confounders (bootstrapping). From 115 hospitals, 1593 patients with KD in the treatment group and 1593 controls were selected for each of the 1000 sample iterations. The median proportion of patients who developed coronary artery abnormalities among the treatment group and controls were 4.6% (95% CI, 3.8%–5.8%) and 8.8% (95% CI, 7.5%–10.0%), respectively: an estimated risk ratio of 0.53 (0.41–0.67). A median of 14.1% (95% CI, 12.4%–15.9%) of the patients in the treatment group and 21.7% (95% CI, 19.8%–23.4%) in the controls had treatment failure: an estimated risk ratio of 0.65 (0.56―0.75). CONCLUSIONS Combination treatment reduced coronary artery abnormality risk by an estimated 47% and treatment failure by 35%. Multiple‐dose corticosteroids may provide benefit in selected patients at high risk for KD.


2010 ◽  
Vol 99 (10) ◽  
pp. 1578-1583 ◽  
Author(s):  
Ho-Chang Kuo ◽  
Chi-Di Liang ◽  
Chih-Lu Wang ◽  
Hong-Ren Yu ◽  
Kao-Pin Hwang ◽  
...  

2010 ◽  
Vol 74 (3) ◽  
pp. 544-551 ◽  
Author(s):  
Ken-Pen Weng ◽  
Kai-Sheng Hsieh ◽  
Tsyr-Yuh Ho ◽  
Shih-Hui Huang ◽  
Chung-Ren Lai ◽  
...  

2013 ◽  
Vol 163 (2) ◽  
pp. 521-526.e1 ◽  
Author(s):  
Tohru Kobayashi ◽  
Tomio Kobayashi ◽  
Akihiro Morikawa ◽  
Kentaro Ikeda ◽  
Mitsuru Seki ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document